Sign in
Not yet taking people in Hong KongNo phase

Surgery Alone or With Bladder Chemotherapy for Intermediate-Risk Non-Muscle-Invasive Bladder Cancer

Compares bladder tumor removal alone with added mitomycin treatment in adults with bladder cancer.

Key facts

Who runs it
Chinese University of Hong Kong
Where
Hong Kong and Shatin, Hong KongSee the 2 sites
Trial code
Registry title
The Role of ERBT Plus Adjuvant Intravesical Induction and Maintenance Chemotherapy for Intermediate-Risk NMIBC
Status
Not yet recruiting
People taking part
440 people, planned
Starts
1 Jan 2027
Expected to end
31 Mar 2030
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • ERBT and Adjuvant MMC Therapy
  • ERBT
Record updated
30 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with intermediate-risk non-muscle-invasive bladder cancer whose tumour was removed in one piece (ERBT) with clear margins and who cannot or will not have intravesical BCG therapy.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Intermediate-risk non-muscle-invasive bladder cancer (NMIBC), confirmed by tissue examination.
Earlier treatment
ERBT (en bloc resection of bladder tumour) must have been done successfully with clear resection margins. People cannot join if they had earlier chemotherapy or BCG instilled into the bladder.

Main reasons for not taking part

  • Any earlier chemotherapy instillations into the bladder
  • Any earlier intravesical BCG therapy
  • Current or past cancer of the upper urinary tract
  • Serious heart disease or severe chronic lung disease (COPD GOLD Stage III or IV)
  • ECOG performance status 2 or higher, pregnancy, or another active cancer

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Age ≥ 18 years old with informed consent
  • ERBT was successfully performed with clear resection margins
  • Histologically confirmed intermediate-risk NMIBC
  • Patients who are ineligible or refused to undergo intravesical BCG therapy

Who cannot take part

  • Any prior use of intravesical induction and/or maintenance chemotherapy instillations
  • Any prior use of intravesical BCG therapy
  • Presence or prior history of upper urinary tract malignancy
  • Presence of clinically significant cardiovascular disease (History of acute myocardial infarction, presence of uncontrolled angina within 3 months before screening, New York Heart Association Class III or IV congestive heart failure, presence of ventricular arrhythmias, or presence of second-degree or third-degree heart block) (20)
  • Presence of GOLD Stage III or IV chronic obstructive pulmonary disease (21)
  • Presence of other active malignancy
  • ECOG performance status ≥ 2 (Ambulatory and capable of all self-care but unable to carry our any work activities)
  • Pregnancy

Where in Hong Kong

  • Prince of Wales HospitalHong Kong, Hong KongContact: Yuen Chun Jeremy O TEOH, MDNot yet recruiting
  • Prince of Wales HospitalShatin, Hong KongContact: Yuen Chun Jeremy O TEOH, MDNot yet recruiting

About the trial

What the trial wants to find out

This is a prospective, multi-centre randomised trial comparing between ERBT plus 1-year of Ad-MMC, versus ERBT alone, in treating intermediate-risk NMIBC.

The 2 groups in the trial

  • ERBT and Ad-MMC groupTreatment being tested

    Subject will receive induction course of intravesical mitomycin C within 4 weeks after ERBT. The induction course consists of six weekly doses (+/-2 days) of intravesical mitomycin C (40mg mitomycin C). Afterwards, patients will receive ten monthly (+/-7 days) doses of intravesical mitomycin C (40mg mitomycin C) up to one year as maintenance course. The whole induction and maintenance course of Ad-MMC lasts for about one year

    Treatment: ERBT and Adjuvant MMC Therapy

  • ERBT GroupExisting treatment, for comparison

    No Adjuvant treatment

    Treatment: ERBT

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomised Trial Investigating The Role of En Bloc Resection of Bladder Tumour Plus Adjuvant Intravesical Induction and Maintenance Chemotherapy for Intermediate-Risk Non-Muscle-Invasive Bladder Cancer
Plain-language title
Surgery Alone or With Bladder Chemotherapy for Intermediate-Risk Non-Muscle-Invasive Bladder CancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 13 November 2026.
Record updated
30 October 2026